Triamcinolone Acetonide in Ocular Therapeutics

Survey of Ophthalmology

Volumn 52, Issue 5, 2007, Pages 503-522

  Jermak, C M ^a,b   Dellacroce, J T ^a   Heffez, J ^a   Peyman, G A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b PainRehab Center of Western New York   (United States)

Author keywords

intravitreal steroid; Kenalog; periocular steroid; sub tenon steroid; triamcinolone acetonide

Indexed keywords

BENZYL ALCOHOL; BETAMETHASONE; BETAMETHASONE ACETATE PLUS BETAMETHASONE SODIUM PHOSPHATE; BUDESONIDE; CORTICOSTEROID; CORTISONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; DRUG PRESERVATIVE; FLUDROCORTISONE; FLUTEX; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; KENAQUART; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; ONCILON A; PREDNISONE; RINETON; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRICINOLON; UNCLASSIFIED DRUG;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; CHALAZION; CORNEA ULCER; CORNEAL ENDOTHELIAL TOXICITY; DEPIGMENTATION; DIABETIC MACULAR EDEMA; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENDOCRINE OPHTHALMOPATHY; ENDOPHTHALMITIS; EYE TOXICITY; EYELID DISEASE; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; PARTICLE SIZE; PERIBULBAR HEMORRHAGE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PTOSIS; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN ATROPHY; UNSPECIFIED SIDE EFFECT; UVEITIS; VERNAL CONJUNCTIVITIS; VITRECTOMY; VOGT KOYANAGI SYNDROME;

GLUCOCORTICOIDS; HUMANS; KERATOCONJUNCTIVITIS; MACULAR EDEMA, CYSTOID; RETINAL DISEASES; TRIAMCINOLONE ACETONIDE; UVEITIS;

EID: 34547953536     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2007.06.004     Document Type: Review

References (140)

1. Alldredge C.D., and Garretson B.R. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 23 (2003) 113-116
2. Andrade R.E., Muccioli C., Farah M.E., et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 137 (2004) 572-574
3. Argenti D., Jensen B.K., Hensel R., et al. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J Clin Pharmacol 40 (2000) 770-780
4. Audren F., Tod M., Massin P., et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 45 (2004) 3435-3441
5. Audren F., Erginay A., Haouchine B., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84 (2006) 624-630
6. Bakri S.J., and Beer P.M. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 34 (2003) 386-390
7. Bashshur Z.F., Ma'luf R.N., Allam S., et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 122 (2004) 1137-1140
8. Becker B. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1 (1971) 1-16
9. Beer P.M., Bakri S.J., Singh R.J., et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110 (2003) 681-686
10. Benhamou N., Massin P., Haouchine B., et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135 (2003) 246-249
11. Bhavan S., Peyman G.A., Conway M.D., et al. Intraocular pressure after low-dose 400ug intravitreal triamcinolone acetonide injection. ARVO abstract (2004) 3945/B406
12. Bill A. Editorial: The drainage of aqueous humor. Invest Ophthalmol 14 (1975) 1-3
13. Burk S.E., Da Mata A.P., Snyder M.E., et al. Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 29 (2003) 645-651
14. Challa J.K., Gillies M.C., Penfold P.L., et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 26 (1998) 277-281
15. Chan C.K., Fan D.S., Chan W.M., et al. Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study. Eye 19 (2005) 625-630
16. Chen S.D., Lochhead J., McDonald B., et al. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol 88 (2004) 843-844
17. Ciardella A.P., Klancnik J., Schiff W., et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 88 (2004) 1131-1136
18. Conway M.D., Canakis C., Livir-Rallatos C., et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29 (2003) 27-33
19. Cubey R.B. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol 95 (1976) 207-208
20. Danis R.P., Ciulla T.A., Pratt L.M., et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
21. Degenring R.F., and Jonas J.B. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137 (2004) 1142-1143
22. Degenring R.F., Kreissig I., and Jonas J.B. [Intraocular triamcinolone for diffuse diabetic macular edema]. Ophthalmologe 101 (2004) 251-254
23. Dominquez A., Quiroga P., Jareno M., et al. El tratamento de enfermedads medicas con triamcinolone intravitrea. Arch Doc Esp Oftalmol 65 (1993) 491-498
24. Duguid I.G., Boyd A.W., and Mandel T.E. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res 11 Suppl (1992) 153-159
25. Ebner R., Devoto M.H., Weil D., et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88 (2004) 1380-1386
26. Elner S.G., Elner V.M., Pavilack M.A., et al. Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells. Lab Invest 66 (1992) 200-211
27. Enaida H., Hata Y., Ueno A., et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina 23 (2003) 764-770
28. Ferrante P., Ramsey A., Bunce C., et al. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Experiment Ophthalmol 32 (2004) 563-568
29. Ferry A.P., Harris W.P., and Nelson M.H. Histopathologic features of subconjunctivally injected corticosteroids. Am J Ophthalmol 103 (1987) 716-718
30. Fingar V.H. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14 (1996) 323-328
31. Flach A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96 (1998) 557-634
32. Francis B.A., Chang E.L., and Haik B.G. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology 103 (1996) 1884-1888
33. François F., and Victoria-Troncoso V. [Mucopolysaccharides and pathogenesis of cortisone glaucoma (author's transl)]. Klin Monatsbl Augenheilkd 165 (1974) 5-10
34. Fraser E.A., Cheema R.A., and Roberts M.A. Triamcinolone acetonide-assisted peeling of retinal internal limiting membrane for macular surgery. Retina 23 (2003) 883-884
35. Furino C., Micelli Ferrari T., Boscia F., et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 23 (2003) 771-776
36. Garber M.I. Methylprednisolone in the treatment of exophthalmos. Lancet 1 (1966) 958-960
37. Gass J.D., and Blodi B.A. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100 (1993) 1536-1546
38. Gaston H., Absolon M.J., Thurtle O.A., et al. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 67 (1983) 487-490
39. Gillies M.C., Kuzniarz M., Craig J., et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112 (2005) 139-143
40. Gillies M.C., Simpson J.M., Luo W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 (2003) 667-673
41. Glaser B.M., Cardin A., and Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 94 (1987) 327-332
42. Heidenkummer H.P., and Kampik A. [Surgical extraction of subretinal pseudotumors in age related macular degeneration. Clinical, morphologic and immunohistochemical results]. Ophthalmologe 92 (1995) 631-639
43. Helm C.J., and Holland G.N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 120 (1995) 55-64
44. Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 74 (1972) 501-504
45. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol 82 (1976) 90-93
46. Hida T., Chandler D., Arena J.E., et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101 (1986) 190-195
47. Ho S.Y., and Lai J.S. Subcutaneous steroid injection as treatment for chalazion: prospective case series. Hong Kong Med J 8 (2002) 18-20
48. Holsclaw D.S., Whitcher J.P., Wong I.G., et al. Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol 121 (1996) 243-249
49. Ip M., Kahana A., and Altaweel M. Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol 18 (2003) 67-73
50. Ip M.S., Gottlieb J.L., Kahana A., et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122 (2004) 1131-1136
51. Jennings T., Rusin M.M., Tessler H.H., et al. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 32 (1988) 385-391
52. Jonas J.B., Akkoyun I., Budde W.M., et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122 (2004) 218-222
53. Jonas J.B., Degenring R.F., Kamppeter B.A., et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 138 (2004) 158-160
54. Jonas J.B., Degenring R.F., Kreissig I., et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 19 (2005) 163-170
55. Jonas J.B., Kreissig I., and Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87 (2003) 24-27
56. Jonas J.B., Kreissig I., and Degenring R.F. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136 (2003) 384-386
57. Jonas J.B., Kreissig I., and Degenring R.F. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 88 (2004) 1557-1562
58. Jonas J.B., and Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132 (2001) 425-427
59. Jonas J.B. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 86 (2002) 1450-1451
60. Jonas J.B. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137 (2004) 560-562
61. Jonas J.B. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 38 (2006) 218-245
62. Kai W., Yanrong J., and Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1152-1159
63. Kalina P.H., Erie J.C., and Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol 113 (1995) 867-869
64. Kalina R.E. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 81 (1969) 788-790
65. Karacorlu M., Ozdemir H., Karacorlu S., et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 19 (2005) 382-386
66. Karacorlu M., Ozdemir H., and Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 81 (2003) 648-652
67. Kimura H., Kuroda S., and Nagata M. Triamcinolone acetonide-assisted peeling of the internal limiting membrane. Am J Ophthalmol 137 (2004) 172-173
68. Kivilcim M., Peyman G.A., El-Dessouky E.S., et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 31 (2000) 474-478
69. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 21 (2001) 4271-4277
70. Lam D.S., Chan C.K., Tang E.W., et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 32 (2004) 569-572
71. Kreines K., and Weinberg I.C. The selection of adrenocorticosteroid preparations. Ohio State Med J 71 (1975) 698, 703-6
72. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
73. Martidis A., Miller D.G., Ciulla T.A., et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 15 (1999) 425-428
74. Massin P., Audren F., Haouchine B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111 (2004) 218-224 discussion 224-5
75. McCarty G.R., and Schwartz B. Increased concentration of glucocorticoid receptors in rabbit iris-ciliary body compared to rabbit liver. Invest Ophthalmol Vis Sci 23 (1982) 525-528
76. McCuen B.W., Bessler M., Tano Y., et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91 (1981) 785-788
77. Micelli Ferrari T., Sborgia L., Furino C., et al. Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 14 (2004) 321-324
78. Modarres M., Parvaresh M.M., and Peyman G.A. Accidental subretinal injection of triamcinolone acetonide. Ophthalmic Surg Lasers 29 (1998) 935-938
79. Moshfeghi A.A., Flynn Jr. H.W., et al. Complications of intravitreal triamcinolone injection. Rev Ophthalmol 4 (2004) 64-67
80. Moshfeghi A.A., Scott I.U., Flynn Jr. H.W., et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 138 (2004) 489-492
81. Moshfeghi D.M., Kaiser P.K., Scott I.U., et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136 (2003) 791-796
82. Mueller A.J., Jian G., Banker A.S., et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 125 (1998) 158-163
83. Mustafa T.A., and Oriafage I.H. Three methods of treatment of chalazia in children. Saudi Med J 22 (2001) 968-972
84. Nelson M.L., Tennant M.T., Sivalingam A., et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23 (2003) 686-691
85. Nozik R.A. Periocular injection of steroids. Trans Am Acad Ophth Otol 76 (1976) 695-704
86. Ober M.D., Barile G.R., Tari S.R., et al. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection. Am J Ophthalmol 142 (2006) 597-600
87. Okada A.A., Wakabayashi T., Morimura Y., et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 87 (2003) 968-971
88. Ozkiris A., Evereklioglu C., Erkiliç K., et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 14 (2004) 543-549
89. Park C.H., Jaffe G.J., and Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136 (2003) 419-425
90. Park D.W., Schatz H., McDonald H.R., et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 104 (1997) 1838-1846
91. Penfold P.L., Wen L., Madigan M.C., et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 121 (2000) 458-465
92. Penfold P.L., Gyory J.F., Hunyor A.B., et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 23 (1995) 293-298
93. Penfold P.L., Wen L., Madigan M.C., et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 43 (2002) 3125-3130
94. Peyman G.A., Cheema R., Conway M.D., et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 20 (2000) 554-555
95. Peyman G.A., and Herbst R. Bacterial endophthalmitis. Treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol 91 (1974) 416-418
96. Pizzarello L.D., Jakobiec F.A., Hofeldt A.J., et al. Intralesional corticosteroid therapy of chalazia. Am J Ophthalmol 85 (1978) 818-821
97. Podos S.M., Becker B., and Morton W.R. High myopia and primary open-angle glaucoma. Am J Ophthalmol 62 (1966) 1038-1043
98. Rechtman E., Allen V.D., Danis R.P., et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 136 (2003) 739-741
99. Rechtman E., Danis R.P., Pratt L.M., et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88 (2004) 344-347
100. Renfro L., and Snow J.S. Ocular effects of topical and systemic steroids. Dermatol Clin 10 (1992) 505-512
101. Rhee D.J., Peck R.E., Belmont J., et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 90 (2006) 999-1003
102. Riordan-Eva P., and Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 8 (1994) 66-69
103. Rohen J.W., Linnér E., and Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res 17 (1973) 19-31
104. Rosenblatt B.J., Shah G.K., Sharma S., et al. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol 243 (2005) 20-25
105. Saini J.S., Gupta A., Pandey S.K., et al. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand 77 (1999) 515-518
106. Sakamoto T., Miyazaki M., Hisatomi T., et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 240 (2002) 423-429
107. Saperstein D.A., Rosenfeld P.J., Bressler N.M., et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 109 (2002) 1499-1505
108. Schindler R.H., Chandler D., Thresher R., et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93 (1982) 415-417
109. Sharma M.C., Lai W.W., and Shapiro M.J. Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 23 (2004) 398-399
110. Shields M.B. Shields' Textbook of Glaucoma (1998), Lippincott Williams & Wilkins, Philadelphia, PA 323-8
111. Singh S., Pal V., and Dhull C.S. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Ind J Ophthalmol 50 (2001) 160-161
112. Smithen L.M., Ober M.D., Maranan L., et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138 (2004) 740-743
113. Smithen L.M., and Spaide R.F. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 138 (2004) 884-885
114. Sommer A., Veraart J., Neumann M., et al. Evaluation of the vasoconstrictive effects of topical steroids by laser-Doppler-perfusion-imaging. Acta Derm Venereol 78 (1998) 15-18
115. Spaeth G.L., Rodrigues M.M., and Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects. Trans Am Ophthalmol Soc 75 (1977) 353-381
116. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
117. Spaide R.F., and Yannuzzi L.A. Cystoid macular edema after cataract surgery. Sem Ophthalmol 8 (1993) 121-129
118. Southren A.L., Dominguez M.O., Gordon G.G., et al. Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body and adjacent corneoscleral tissue of the rabbit following topical administration of various glucocorticoids. A rapid screening method for glucocorticoid activity. Invest Ophthalmol Vis Sci 24 (1983) 147-152
119. Southren A.L., Gordon G.G., l'Hommedieu D., et al. 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. Invest Ophthalmol Vis Sci 26 (1985) 393-395
120. Tanner V., Kanski J.J., and Frith P.A. Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Eye 12 Pt 4 (1998) 679-685
121. Tano Y., Chandler D., and Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 90 (1980) 810-816
122. Tano Y., Chandler D.B., McCuen B.W., et al. Glucocorticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol 91 (1981) 184-189
123. ___: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102 (1995) 1425-1433
124. The SCORE Study Clinical Studies Database, NEI: http://www.nei.nih.gov/neitrials/viewStudyWeb.aspx?id=99. Accessed 7/9/07
125. Thomas I.D., and Hart J.K. Retrobulbar repository corticosteroid therapy in thyroid ophthalmopathy. Med J Aust 2 (1974) 484-487
126. Thompson J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 141 (2006) 629-637
127. Ticho U., Lahav M., Berkowitz S., et al. Ocular changes in rabbits with corticosteroid-induced ocular hypertension. Br J Ophthalmol 63 (1979) 646-650
128. Tranos P.G., Wickremasinghe S.S., Stangos N.T., et al. Macular edema. Surv Ophthalmol 49 (2004) 470-490
129. Tu E.Y., Culbertson W.W., Pflugfelder S.C., et al. Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. Ophthalmology 102 (1995) 718-724
130. Schmidt-Erfurth U., Schlötzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
131. Vidaurri L.J., and Pe'er J. Intralesional corticosteroid treatment of chalazia. Ann Ophthalmol 18 (1986) 339-340
132. Vie R. Glaucoma and amaurosis associated with long-term application of topical corticosteroids to the eyelids. Acta Derm Venereol 60 (1980) 541-542
133. Weinreb R.N., Bloom E., Baxter J.D., et al. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 21 (1981) 403-407
134. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 36 (1992) 373-384
135. Wright P.L., Wilkinson C.P., Balyeat H.D., et al. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol 106 (1988) 740-744
136. Yamakiri K., Uchino E., Kimura K., et al. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol 138 (2004) 650-652
137. Yoshikawa K., Kotake S., Ichiishi A., et al. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 39 (1995) 71-76
138. Zamir E., Read R.W., Smith R.E., et al. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. Ophthalmology 109 (2002) 798-805 discussion 805-7
139. Zimmerman T., Kooner K., Sharir M., et al. Textbook of ocular pharmacology (1997), Lippincott-Raven, Philadelphia pp. 683-4
140. Zugerman C., Saunders D., and Levit F. Glaucoma from topically applied steroids. Arch Dermatol 112 (1976) 1326